Exelixis (EXEL) Announces Presentation of Cobimetinib, Vemurafenib, Atezolizumab Combo Phase 1b Data in BRAF V600
- Wall Street closes higher as investors digest earnings, megacap outlook
- Tesla touts acceleration of new models, but Q1 results fall short of estimates
- JPMorgan is worried about further S&P 500 sell-off potential
- Oil rises as dollar slips, focus shifts to economic data
- China acquired top-end Nvidia AI chips despite recent US ban- Reuters
- Fisker (FSR) Appoints Michael Healy as Chief Restructuring Officer
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- China acquired top-end Nvidia AI chips despite recent US ban- Reuters
- Wolfe Research Downgrades Warner Brothers Discovery (WBD) to Underperform, 'out of concern that an incipient advertising downturn put guidance at risk'
- Forward Air (FWRD) Appoints Shawn Stewart as CEO
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
- After-hours movers: Cadence Design Systems, Cleveland-Cliffs, Riot Platforms, and more
- Midday movers: Tesla, Li Auto and CNH Industrial fall; Salesforce rises
- Midday movers: Netflix, Super Micro fall; Paramount Global gains
Piper Jaffray Upgrades Exelixis (EXEL) to Overweight
October 10, 2016 9:09 AM EDTPiper Jaffray upgraded Exelixis (NASDAQ: EXEL) from Neutral to Overweight.
For an analyst ratings summary and ratings history on Exelixis click here. For more ratings news on Exelixis click here.
Shares of Exelixis closed at $12.95 yesterday.
... MoreGenentech (RHHBY) Announces Significant Data from TECENTRIQ Phase 3 Data in Specific Lung Cancer
October 10, 2016 6:29 AM EDTGenentech, a member of the Roche Group (OTC: RHHBY), announced data from the positive, pivotal Phase III OAK study of TECENTRIQ (atezolizumab) at the European Society of Medical Oncology (ESMO) 2016 Annual Meeting in Copenhagen, Denmark. The study showed TECENTRIQ helped people live a median of 13.8 months, 4.2 months longer than those treated with docetaxel chemotherapy (median overall survival [OS]: 13.8 vs. 9.6 months; HR = 0.73, 95% CI: 0.62 - 0.87). The OAK study evaluated people with non-small cell lung cancer (NSCLC) whose disease had progressed on or after treatment with one or more platinum-based chemotherapy (second-line and third-line). The study enrolled people... More
Exelixis (EXEL) Announces Encouraging Cabozantinib Combo Phase 1 Data in Genitourinary Tumors
October 7, 2016 7:36 AM EDTExelixis, Inc. (Nasdaq: EXEL) announced results from a phase 1 trial of cabozantinib in combination with nivolumab in patients with previously treated genitourinary tumors. The findings will be presented during a poster discussion session (Abstract #774PD) on October 9 at the European Society for Medical Oncology (ESMO) 2016 Congress, which is being held in Copenhagen, October 7 11, 2016.
The treatment landscape for advanced, intractable cancers such as metastatic urothelial carcinoma is continuously evolving and the use of combination therapies may improve outcomes for patients in need of new options, said Andrea Apolo, M.D., Genitourinary Malignancies Branch, Center for Cancer... More